Novacyt (LON:NCYT)
33.70p-0.88%
Spriggl Score: Weak— sign in to explore; full breakdown with Premium
Last 30 trading days
Spriggl AI Verdict
“Major cost restructuring could extend runway but execution risk mid-turnaround keeps this speculative.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Novacyt
Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer De…
- Sector:
- Healthcare
- Industry:
- Medical Devices
- Market Cap:
- £25.4M
Recent dividends
No recent dividends recorded.
Get the full Spriggl analysis — free
A free Spriggl account gets you the screener, a watchlist, AI verdicts and a free full report every day — across Novacyt and 1,500+ UK and US stocks. The full score breakdown and AI analysis come with Premium.
Start free